MSc MBA - BiondVax Pharmaceuticals CEO Director
| BVXVDelisted Stock | USD 1.35 0.03 2.17% |
Insider
MSc MBA is CEO Director of BiondVax Pharmaceuticals
| Age | 47 |
| Phone | 972 8 930 2529 |
| Web | https://www.biondvax.com |
BiondVax Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3089) % which means that it has lost $0.3089 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (56.0153) %, meaning that it created substantial loss on money invested by shareholders. BiondVax Pharmaceuticals' management efficiency ratios could be used to measure how well BiondVax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.BiondVax Pharmaceuticals currently holds 21.54 M in liabilities. BiondVax Pharmaceuticals has a current ratio of 1.68, which is within standard range for the sector. Note, when we think about BiondVax Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Christopher Garcia | Surrozen | N/A | |
| Brian Varnum | Armata Pharmaceuticals | 64 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Matthew Shatzkes | Aditxt Inc | N/A | |
| Wim Souverijns | Pharvaris BV | 53 | |
| Morgan Conn | Pharvaris BV | 55 | |
| Calvin MD | Surrozen | N/A | |
| Erin Butler | Armata Pharmaceuticals | N/A | |
| Sanjay Chanda | AN2 Therapeutics | 59 | |
| Elizabeth Evans | Vaccinex | 51 | |
| MS JD | Surrozen | 62 | |
| Daniela Santiesteban | Salarius Pharmaceuticals | N/A | |
| Duane BA | Armata Pharmaceuticals | 74 | |
| CPA CPA | BioLineRx | 48 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| John Lacey | BioLineRx | N/A | |
| Ilan Cohn | Can Fite Biopharma | 70 | |
| Jael MSc | BioLineRx | N/A | |
| Roeland Nusse | Surrozen | 74 | |
| Rowena Albanna | Aditxt Inc | 58 | |
| , MBA | Molecular Partners AG | 51 | |
Management Performance
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 |
BiondVax Pharmaceuticals Leadership Team
Elected by the shareholders, the BiondVax Pharmaceuticals' board of directors comprises two types of representatives: BiondVax Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BiondVax. The board's role is to monitor BiondVax Pharmaceuticals' management team and ensure that shareholders' interests are well served. BiondVax Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BiondVax Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| BSc Eng, Chief Officer | ||
| Tamar BenYedidia, Chief Scientific Officer | ||
| Dalit Fischer, Head RD | ||
| MSc MBA, CEO Director | ||
| Moran LLB, Chief Staff |
BiondVax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BiondVax Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 | |||
| Current Valuation | 21.94 M | |||
| Shares Outstanding | 3.65 M | |||
| Shares Owned By Insiders | 20.01 % | |||
| Shares Owned By Institutions | 10.69 % | |||
| Number Of Shares Shorted | 4.88 K | |||
| Price To Earning | (4.91) X | |||
| Price To Book | 7.48 X | |||
| EBITDA | (10.5 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in BiondVax Stock
If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |